<DOC>
	<DOCNO>NCT01308606</DOCNO>
	<brief_summary>The purpose study compare absorption TMC435 formulate 2 different type capsule . After , absorption one chosen TMC435 capsule compare take fast condition together standard high-fat meal . This do healthy volunteer .</brief_summary>
	<brief_title>TMC435-TiDP16-C116 - Relative Bioavailability Food Effect Study</brief_title>
	<detailed_description>This open-label , randomize , single-dose , crossover trial healthy volunteer . Crossover mean participant may receive different intervention sequentially trial . Randomized mean assign treatment sequence chance , like flip coin . Open-label mean physician know treatment receive . The study consist 3 phase : screening phase , treatment phase follow-up phase . Total study duration individual participant 6 7 week . Once find eligible screening phase , participant take part one two part treatment phase . In first part , group 24 participant receive two treatment session , A B . The order treatment give determine chance . Treatment A single dose TMC345 one formulation ( 1 capsule ) . Treatment B single dose TMC435 another formulation ( 1 type capsule ) . Both treatment take without food . In 2 session , least 7 day . In second part , another group 24 participant receive 3 treatment session , C , D , E. The order treatment give determine chance . All 3 treatment consist single dose TMC435 one 2 formulation give first part . In Treatment C give without food , Treatment D standardize breakfast Treatment E high-fat breakfast . In session , least 7 day . For treatment session , participant enter study center day dose remain evening day . The 3 follow morning , participant come back study center . Five 7 day dose , participant last follow-up visit study center ( follow-up phase ) . During study , safety monitor , treatment phase , specify timepoints , blood sample take pharmacokinetic evalutions ( effect body drug ) . In every treatment session , single oral 150 mg TMC435 capsule give . One formulation gelatin capsule . The formulation hydroxypropylmethylcellulose ( HPMC ) capsule .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Nonsmokers least 3 month prior screen Have body mass index 18.0 30.0 kg per square meter Be healthy basis physical examination , medical history , vital sign , clinical laboratory test perform screen Use disallow therapy , include overthecounter product dietary supplement Having previously participate multipledose trial 3 singledose trial TMC435 Received investigational drug use investigational medical device within 90 day plan start treatment History evidence current use alcohol , barbiturate , amphetamine , recreational , narcotic drug use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>TMC435-TiDP16-C116</keyword>
	<keyword>TMC435-C116</keyword>
	<keyword>TMC435</keyword>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hep C</keyword>
	<keyword>healthy volunteer</keyword>
</DOC>